Ongoing insurance reinstatement costs for a global pharmaceutical manufacturer
- Case Study
30/07/2019
Brief
A large multi-national pharmaceutical company had a requirement for regular insurance valuations of its global manufacturing facilities including plant & equipment and buildings.
Work
Valuations were performed at over 65 global locations, followed by a planned programme of periodic revaluations to provide annual sums insured.
The assets include extremely high specification, often unique, research, test and production machinery and equipment requiring multi-disciplinary approaches to valuation.
Where a significant new build project had taken place valuations were performed to calculate what effect the additional capital expenditure would have on the sums insured. minimizing any premium increase.
Outcome
After 25 years insurance valuation advice is still provided to three of the largest global pharmaceutical companies demonstrating our unrivalled experience and knowledge in this sector.
